Evidence map›Paper›PMID 34298818›Full record

ReviewCancers2021

Reconsideration of the Appropriate Dissection Range Based on Japanese Anatomical Classification for Resectable Pancreatic Head Cancer in the Era of Multimodal Treatment.

Yuichi Nagakawa, Naoya Nakagawa, Chie Takishita, Ichiro Uyama, Shingo Kozono, Hiroaki Osakabe, Kenta Suzuki, Nobuhiko Nakagawa, Yuichi Hosokawa, Tomoki Shirota and 4 more

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Yuichi NagakawaDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo 160-8402, Japan.ORCID 0000-0003-1169-8160
Naoya NakagawaDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo 160-8402, Japan.
Chie TakishitaDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo 160-8402, Japan.
Ichiro UyamaDepartment of Advanced Robotic and Endoscopic Surgery, Fujita Health University, Toyoake 470-1192, Aichi, Japan.
Shingo KozonoDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo 160-8402, Japan.
Hiroaki OsakabeDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo 160-8402, Japan.
Kenta SuzukiDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo 160-8402, Japan.
Nobuhiko NakagawaDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo 160-8402, Japan.ORCID 0000-0003-2095-1308
Yuichi HosokawaDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo 160-8402, Japan.
Tomoki ShirotaDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo 160-8402, Japan.
Masayuki HondaDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo 160-8402, Japan.
Tesshi YamadaDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo 160-8402, Japan.ORCID 0000-0002-6843-7482
Kenji KatsumataDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo 160-8402, Japan.
Akihiko TsuchidaDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo 160-8402, Japan.
Tokyo Medical University · JPFujita Health University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with resectable pancreatic cancer are considered to already have micro-distant metastasis, because most of the recurrence patterns postoperatively are distant metastases. Multimodal treatment dramatically improves prognosis; thus, micro-distant metastasis is considered to be controlled by chemotherapy. The survival benefit of "regional lymph node dissection" for pancreatic head cancer remains unclear. We reviewed the literature that could be helpful in determining the appropriate resection range. Regional lymph nodes with no suspected metastases on preoperative imaging may become areas treated with preoperative and postoperative adjuvant chemotherapy. Many studies have reported that the R0 resection rate is associated with prognosis. Thus, "dissection to achieve R0 resection" is required. The recent development of high-quality computed tomography has made it possible to evaluate the extent of cancer infiltration. Therefore, it is possible to simulate the dissection range to achieve R0 resection preoperatively. However, it is often difficult to distinguish between areas of inflammatory changes and cancer infiltration during resection. Even if the "dissection to achieve R0 resection" range is simulated based on the computed tomography evaluation, it is difficult to identify the range intraoperatively. It is necessary to be aware of anatomical landmarks to determine the appropriate dissection range during surgery.

Indexed as

adjuvant chemotherapylymph node dissectionmesopancreasnerve and fibrous tissuespancreatic cancerpancreaticoduodenectomyR0 resectionsuperior mesenteric artery

Identifiers

PMID34298818
PMCPMC8303207
OpenAlexW3184549698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.